#United States #New York #Parkinson's Disease #Healthcare Costs #Michael J. Fox Foundation

Financial Impact of Parkinson's Disease in 2024

According to a recent report by The Michael J. Fox Foundation for Parkinson's Research, the economic impact of Parkinson's disease and atypical parkinsonisms has reached a staggering $82.2 billion in the United States in 2024, surpassing earlier projections. This report marks the most comprehensive evaluation to date regarding the economic burden associated with these conditions, underscoring the significant financial strain faced by individuals living with the disease and their families, as well as the government.

The findings reveal that these annual costs not only exceeded the previously estimated $79 billion projected for 2037 but did so over a decade earlier than anticipated. Without further intervention, annual expenditures are projected to escalate to over $112 billion by 2045. Currently, around 1.2 million people in the U.S. are living with Parkinson's or related atypical conditions.

Breakdown of Costs

The report outlines a detailed analysis of the $82.2 billion spent annually:

• - $23.8 billion is attributed to direct medical costs, such as hospitalizations, outpatient care, and medications.
• - $58.4 billion accounts for indirect and non-medical expenses, encompassing lost income, disability, and unpaid caregiving.

Caregivers and Financial Strain

The burden extends beyond the patients themselves; caregivers shoulder much of the economic impact, totaling $8.3 billion in lost income and productivity due to reduced working hours, premature retirement, or leaving the workforce. Notably, nearly 40% of those with Parkinson's rely on unpaid caregivers, many of whom are also facing financial hardship due to their caregiving duties. The data reveals a troubling trend, with over 20% of caregivers working fewer hours or retiring early, while 34% had to cancel their own medical appointments due to the demands of caregiving.

Patients themselves encounter substantial costs prior to a formal diagnosis, averaging more than $10,000 in additional medical expenses in the year leading up to diagnosis, reflecting a prolonged and often uncertain journey towards identifying the disease.

Philanthropist Phil Stelzer, a resident of Defiance, Ohio, shared his personal struggles with the diagnosis, stating, “My wife and I have had to reorganize how we live now, as well as our plans and dreams for the future.” He added, “Fighting Parkinson's disease is costly, which reduces what we can save for our future.”

Federal Financial Commitment

The growing financial implications of Parkinson's disease also translate into significant costs for federal programs. Approximately 90% of the direct medical costs are covered by Medicare and Medicaid, which collectively amount to over $25 billion spent in 2024 on healthcare for those afflicted by Parkinson's and related conditions.

These findings were released shortly before over 300 advocates from 49 states gathered in Washington D.C. for the 2026 Parkinson's Policy Forum. Advocates, including patients, caregivers, researchers, and organizational leaders, appealed to Congress for increased federal funding for National Institutes of Health (NIH) research, addressing environmental risk factors linked to the disease, and initiating a coordinated federal initiative to improve prevention, diagnosis, and treatment.

Collaborative Efforts in Reporting

This report builds upon a 2019 finding that estimated Parkinson's-related costs at $52 billion in 2017. By expanding the definition of financial burden to encompass care costs, lost productivity, non-medical expenses, and expenses incurred before diagnosis, the report showcases not only the economic strain but also the personal toll on millions affected.

For the first time, the analysis includes detailed statistics on atypical parkinsonisms, which account for approximately 122,000 of the 1.2 million individuals diagnosed. Across various data sources, including Medicare claims and community impact surveys, the report now offers a clearer picture of both the prevalence and economic impact of these diseases in America.

The findings have garnered the attention of major nonprofit organizations, including the Parkinson's Foundation and the American Parkinson Disease Association, who emphasize the urgent need for increased federal investment of at least $600 million annually towards finding better treatments and eventual cures for Parkinson's disease.

Conclusion

The comprehensive nature of this report sheds light on the multifaceted challenges associated with living with Parkinson's disease. It underscores the urgency for more significant investment in research and innovative treatments to alleviate both the personal and economic burdens faced by individuals and families grappling with this debilitating condition. As Debi Brooks, co-founder of The Michael J. Fox Foundation, states, “Investing in research today is a strategic commitment to a future where families experience less pressure and federal programs reduce costs.”